Clairvoyant Therapeutics
29.11.2023 22:46:30 CET | ACCESS Newswire | Press release
VANCOUVER, BC / ACCESSWIRE / November 29, 2023 / Clairvoyant Therapeutics Inc. (www.clairvoyantrx.com), the clinical-stage pharmaceutical company developing psilocybin therapy for alcohol use disorder (AUD), today announced that it has randomized more than 50 per cent of the expected 128 subjects for its 24-week Phase 2b clinical trial of synthetic psilocybin (25mg oral capsule). The double-blind, randomized controlled trial was initiated in October 2022 and is designed to assess multiple efficacy and safety endpoints.
"We are pleased that the pace of subject enrollment is at the upper end of our expectations. We are on track for an interim data read out in February 2024 and a top line read out in Q2 2024," stated Damian Kettlewell, CEO, Clairvoyant.
"Our goal is to be the first company in the world to obtain regulatory approval for the clinical use of psilocybin in AUD. The medical benefits of psychedelic compounds like psilocybin have been supressed for decades. We are pleased that regulatory authorities are now engaged in evidence-based approaches to review these potentially remarkable compounds."
Clairvoyant has been motivated to explore psilocybin therapy for AUD as a result of pioneering academic work by researchers in the U.S. Positive clinical results will support Clairvoyant's goal to help millions of AUD patients around the world.
Alcohol is the leading risk factor for overall burden of disease among men and a significant risk factor among women (source: WHO Global Status Report on Alcohol and Health 2014). A regional study recently reported that fewer than 5 per cent of patients diagnosed with moderate to severe alcohol use disorder receive recommended medications (source: BC Centre for Substance Use, 2023).
About Clairvoyant Therapeutics
Clairvoyant Therapeutics is a Canadian biotechnology company trailblazing a path to global mental health through psilocybin therapy. Clairvoyant's speed-to-market clinical strategy is designed to enable psilocybin therapy in the EU, UK & Canada to treat patients living with Alcohol Use Disorder (AUD) beginning in 2026.
The company's exceptional team, with deep clinical development experience, has made Clairvoyant the most advanced company developing psilocybin therapy for the treatment of AUD. Clairvoyant is a member of Life Sciences BC.
Additional information about Clairvoyant's clinical trial may be found at ClinicalTrials.gov
-30-
For more information:
Damian Kettlewell
damian@clairvoyantrx.com
SOURCE: Clairvoyant Therapeutics
View source version on accesswire.com:
https://www.accesswire.com/810748/clairvoyant-surpasses-50-per-cent-randomization-in-its-phase-2b-psilocybin-therapy-trial-for-alcohol-use-disorder
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Lawline Exits Beta and Launches Full AI Legal Platform for Businesses and Individuals5.5.2026 15:00:00 CEST | Press release
Sweden's most visited legal platform, recognised among the Nordics' top 9 AI legal startups alongside Legora and others, moves out of beta after surpassing 7,000 registered users, expanding its offering for companies, organisations, and individuals. STOCKHOLM, SE / ACCESS Newswire / May 5, 2026 / Lawline, Sweden's most visited legal platform, today announced the official launch of its AI-driven legal platform, marking its transition out of beta. The launch introduces a significantly expanded product offering aimed at businesses, organisations, and individuals seeking accessible, reliable legal support in everyday decision-making. Lawline AI was first released in beta in February 2026 and has since attracted more than 7,000 registered users. With today's full launch, Lawline introduces a broader suite of capabilities designed to bring legal support closer to where decisions are actually made. "Legal support has traditionally been something you access after the fact, often when problems
Digi Power X Signs AI Colocation Agreement with Leading AI Compute Company for 40 MW Data Center in Columbiana, Alabama5.5.2026 13:30:00 CEST | Press release
MIAMI, FL / ACCESS Newswire / May 5, 2026 / Digi Power X Inc. (Nasdaq:DGXX)(Cboe Canada:DGX) (the "Company" or "Digi Power X"), an AI data center infrastructure operator, today announced the execution of a Master Services Agreement (the "Agreement") with Cerebras Systems (the "Customer") for the colocation of a purpose-built, 40 megawatt ("MW") AI data center campus located in Columbiana, Alabama (the "Facility"). The initial 10-year term is valued at approximately $1.1 billion, with total potential contract value of up to $2.5 billion inclusive of renewal terms - underpinned by a structure that provides Digi Power X with long-term revenue visibility, and Cerebras with guaranteed data center capacity, from the first day of service. Digi Power X will develop and deliver the Facility in two phases: Phase 1 comprising 15 MW of IT load, followed by Phase 2 delivering an incremental 25 MW for a combined total of 40 MW. The Facility will be purpose-built to Tier III infrastructure standards
Camino Appointments Senior Management to Build and Operate the Puquios Copper Mine in Chile and for Corporate Development5.5.2026 12:00:00 CEST | Press release
VANCOUVER, BC / ACCESS Newswire / May 5, 2026 / Camino Minerals Corporation (TSXV:COR)(OTCID:CAMZF) ("Camino" or the "Company") is pleased to announce key appointments to its management and operational team to support the advancement of the Puquios copper project ("Puquios" or the "Project") in Chile toward construction and for corporate development. These appointments will further strengthen the Company's operational, financial, and strategic capabilities as it transitions towards development and production in Chile and corporate growth. The Company along with its partner Nittetsu Mining Co., Ltd. ("Nittetsu") has appointed Marcelo Bruna as Chief Executive Officer of Cuprum SpA, the established Chilean company to advance the development of the Puquios copper mine, a 50/50 Joint Venture with Nittetsu. Based in Santiago, Marcelo will manage the Chilean operations. Marcelo is a senior mining executive with over 30 years of experience in project development and operations. He has overseen
Medical Component Specialists to Support Advanced Catheter Innovation at The Catheter R&D Masterclass in Ireland4.5.2026 21:30:00 CEST | Press release
BELLINGHAM, MA / ACCESS Newswire / May 4, 2026 / Medical Component Specialists (MCS), a premier manufacturer of precision medical components, today announced its participation as a supporting organization at The Catheter R&D Masterclass. Hosted by Eyedea Medtech, the highly anticipated event will take place May 28-29, 2026, at the Prototyping and Education Facility in Westport, Mayo, Ireland. The Catheter Systems Lab is an exclusive, dual-purpose educational program designed for senior engineers with over a decade of experience in catheter-based medical device development. Over the course of two days, industry leaders will engage in a deep exploration of catheter design, materials science, structural reinforcement, and end-to-end manufacturing pathways. As a supporting organization, Medical Component Specialists will play a vital role in the event's structured insight and data capture initiatives. The masterclass will facilitate meaningful technical dialogue, allowing MCS to gain direc
Pacific Avenue Capital Partners Enters into Exclusive Negotiations to Acquire ESE World, Amcor's European Waste Container Business4.5.2026 09:30:00 CEST | Press release
LOS ANGELES, CA AND PARIS, FR / ACCESS Newswire / May 4, 2026 / Pacific Avenue Capital Partners ("Pacific Avenue"), a global private equity firm focused on corporate carve-outs and other complex transactions in the middle market, announced today that an affiliate of Pacific Avenue has entered into exclusive negotiations to acquire ESE World (the "Company" or "ESE") from Amcor, one of the world's leading global packaging companies. ESE is the foremost European manufacturer of both plastic and steel waste containers and a provider of associated waste management services. The Company generates approximately €300m of revenues and serves customers across the world from its three manufacturing facilities in Germany (Neuruppin and Olpe) and France (Crissey). Under Pacific Avenue's stewardship, ESE will focus its efforts on meeting the needs of its customers and executing several growth initiatives tied to operational improvement, geographic expansion, and strategic add-on acquisitions. Pacifi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom